-
Mashup Score: 6
Background: Inflammatory breast cancer (IBC) is a rare and poorly characterized type of breast cancer with an aggressive clinical presentation. The biological mechanisms driving the IBC phenotype are relatively undefined, partially due to a lack of comprehensive, large-scale genomic studies and limited clinical cohorts. Patients and Methods: A retrospective analysis of 2457 patients with metastatic breast cancer who underwent targeted tumor-only DNA-sequencing was performed at Dana-Farber Cancer Institute. Clinicopathologic, single nucleotide variant (SNV), copy number variant (CNV) and tumor mutational burden (TMB) comparisons were made between clinically confirmed IBC cases within a dedicated IBC center versus non-IBC cases. Results: Clinicopathologic differences between IBC and non-IBC cases were consistent with prior reports, including IBC being associated with younger age at diagnosis, higher grade, and enrichment with hormone receptor (HR)-negative and HER2-positive tumors. The m
Source: www.biorxiv.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
Background: Inflammatory breast cancer (IBC) is a rare and poorly characterized type of breast cancer with an aggressive clinical presentation. The biological mechanisms driving the IBC phenotype are relatively undefined, partially due to a lack of comprehensive, large-scale genomic studies and limited clinical cohorts. Patients and Methods: A retrospective analysis of 2457 patients with metastatic breast cancer who underwent targeted tumor-only DNA-sequencing was performed at Dana-Farber Cancer Institute. Clinicopathologic, single nucleotide variant (SNV), copy number variant (CNV) and tumor mutational burden (TMB) comparisons were made between clinically confirmed IBC cases within a dedicated IBC center versus non-IBC cases. Results: Clinicopathologic differences between IBC and non-IBC cases were consistent with prior reports, including IBC being associated with younger age at diagnosis, higher grade, and enrichment with hormone receptor (HR)-negative and HER2-positive tumors. The m
Source: www.biorxiv.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 12PARP Inhibitors for Breast Cancer Treatment - 21 day(s) ago
This narrative review summarizes the literature supporting the use of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors for breast cancer treatment, as well as potential future research directions.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 12PARP Inhibitors for Breast Cancer Treatment - 21 day(s) ago
This narrative review summarizes the literature supporting the use of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors for breast cancer treatment, as well as potential future research directions.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 21
Summary. Precision drug development is focusing on targeting tumor cell surface proteins for therapeutic delivery, maximizing biomarker identified on-target damage to the tumor while minimizing toxicity. A recent article demonstrated high expression of B7-H4 antigen on resistant ovarian cancer cells and described preclinical activity of B7-H4–directed antibody–drug conjugate.See related article by Gitto et al., p. 1567
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17
CA: A Cancer Journal for Clinicians is ACS’ flagship clinical oncology journal publishing information about the prevention, early detection, and treatment of cancer.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17
CA: A Cancer Journal for Clinicians is ACS’ flagship clinical oncology journal publishing information about the prevention, early detection, and treatment of cancer.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5
AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with unresectable or metastatic hormone re ceptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior systemic therapy for unresectable or metastatic disease. The Prescription Drug User Fee Act date, the US Food and Drug Administration (FDA) action date for its regulatory decision, is during
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Resources for Patients with Brain Metastasis | Breast Cancer Brain Mets | Leptomeningeal Disease (LMD) | MBCBrainmets.org - 2 month(s) ago
As a one-stop resource hub for breast cancer patients living with brain metastasis, we are committed to sharing cutting-edge information and resources in a simple format. Curated by fellow patients and supported by nonprofit funding, our mission is to connect you to knowledge and support tailored specifically to your needs.
Source: MBCBrainmets.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Resources for Patients with Brain Metastasis | Breast Cancer Brain Mets | Leptomeningeal Disease (LMD) | MBCBrainmets.org - 2 month(s) ago
As a one-stop resource hub for breast cancer patients living with brain metastasis, we are committed to sharing cutting-edge information and resources in a simple format. Curated by fellow patients and supported by nonprofit funding, our mission is to connect you to knowledge and support tailored specifically to your needs.
Source: MBCBrainmets.orgCategories: General Medicine News, Hem/OncsTweet
RT @npriedig: Clinicogenomic characterization of inflammatory breast cancer https://t.co/1nNr4MFwU2